The Efficacy of Anlotinib
DISEASE PROGRESSION, DISEASE, GIST
At the end of the study, the clinical trial had met the pre-specified primary endpoint. The median follow-up time was 18.0 months (95% CI, 15.8-21.2). Forty-six patients had GIST progression while 15 patients died and 1 patient was lost to follow-up. Among the 64 patients, 7 (10.9%) patients had partial response, 39 (60.9%) patients had stable disease, 15 (23.4%) patients had disease progression, and 3 patients were not evaluated because of less than one cycle of anlotinib treatment. DCR was 71.8%. The median PFS was 8.0 months (95% CI, 4.7-11.3 months) (The median PFS of anlotinib second-line therapy in metastatic GIST.